Molecular pathogenesis of viral hepatitis.
The global burden of chronic liver disease caused by persistent infection with hepatitis B and C viruses has meant the urgent development of therapeutic strategies designed to control active replication and therefore prevent subsequent clinical sequelae. Advances in these therapeutic strategies are now clearly happening, mainly as a consequence of a better understanding of the viral life cycle and the unique pathogenesis of each disease. Further progress should continue as further insights into the virus-cell relationship are derived, which will sharpen attention on specific viral targets as well as shift and enhance host cytokine responses.
Locarnini
S
S
Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia. stephenL@hna.ffh.vic.gov.au
D000998:Antiviral Agents / Q000494:pharmacology; D016207:Cytokines / Q000276:immunology; D006509:Hepatitis B / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D006526:Hepatitis C / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D006801:Humans; D014779:Virus Replication
D000998:Antiviral Agents; D016207:Cytokines